Dr. Julian Adams Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Adams has more than 35 years of experience in drug discovery and development. From 2003 to 2016, Dr. Adams held roles of increasing responsibility at Infinity Pharmaceuticals, Inc., where he built and led the company’s R&D efforts which ultimately led to the approval of duvelisib, also known as Copiktra®, for the treatment of certain leukemias and lymphomas. Prior to joining Infinity, from 1999 to 2003, Dr. Adams served as a Senior Vice President at Millenium Pharmaceuticals, where he led the development of bortezomib, also known as Velcade®, for the treatment of multiple myeloma. He has served on the boards of directors of numerous biotechnology companies, and currently serves as the Chairman of the board of directors of Elicio Therapeutics. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry.
As the Chief Executive Officer und Director of Gamida Cell Ltd, the total compensation of Julian Adams at Gamida Cell Ltd is $2,232,000. There are no executives at Gamida Cell Ltd getting paid more.
Julian Adams is 65, he's been the Chief Executive Officer und Director of Gamida Cell Ltd since 2017. There are 1 older and 19 younger executives at Gamida Cell Ltd. The oldest executive at Gamida Cell Ltd is Dr. Julian Adams Ph.D., 66, who is the CEO & Director.
Julian's mailing address filed with the SEC is C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON, MA, 02116.
Over the last 3 years, insiders at Gamida Cell Ltd have traded over $0 worth of Gamida Cell Ltd stock and bought 85,483 units worth $132,499 . The most active insiders traders include Stephen T Wills, Robert I Blum und Jeremy Blank. On average, Gamida Cell Ltd executives and independent directors trade stock every 0 days with the average trade being worth of $699. The most recent stock trade was executed by Stephen T Wills on 30 September 2022, trading 9,677 units of GMDA stock currently worth $14,999.
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
Gamida Cell Ltd executives and other stock owners filed with the SEC include: